Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
Norway

PMID:25473830  

The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.

Nicole F Liachko | Pamela J McMillan | Timothy J Strovas | Elaine Loomis | Lynne Greenup | Jill R Murrell | Bernardino Ghetti | Murray A Raskind | Thomas J Montine | Thomas D Bird | James B Leverenz | Brian C Kraemer
PLoS genetics | 2014

Pathological aggregates of phosphorylated TDP-43 characterize amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP), two devastating groups of neurodegenerative disease. Kinase hyperactivity may be a consistent feature of ALS and FTLD-TDP, as phosphorylated TDP-43 is not observed in the absence of neurodegeneration. By examining changes in TDP-43 phosphorylation state, we have identified kinases controlling TDP-43 phosphorylation in a C. elegans model of ALS. In this kinome-wide survey, we identified homologs of the tau tubulin kinases 1 and 2 (TTBK1 and TTBK2), which were also identified in a prior screen for kinase modifiers of TDP-43 behavioral phenotypes. Using refined methodology, we demonstrate TTBK1 and TTBK2 directly phosphorylate TDP-43 in vitro and promote TDP-43 phosphorylation in mammalian cultured cells. TTBK1/2 overexpression drives phosphorylation and relocalization of TDP-43 from the nucleus to cytoplasmic inclusions reminiscent of neuropathologic changes in disease states. Furthermore, protein levels of TTBK1 and TTBK2 are increased in frontal cortex of FTLD-TDP patients, and TTBK1 and TTBK2 co-localize with TDP-43 inclusions in ALS spinal cord. These kinases may represent attractive targets for therapeutic intervention for TDP-43 proteinopathies such as ALS and FTLD-TDP.

Pubmed ID: 25473830

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NINDS NIH HHS, United States
    Id: 5P50NS2062684-02
  • Agency: NIA NIH HHS, United States
    Id: P01 AG017586
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS064131
  • Agency: NIA NIH HHS, United States
    Id: P50 AG005136
  • Agency: NIA NIH HHS, United States
    Id: 2P50AG005136-27
  • Agency: NINDS NIH HHS, United States
    Id: R01NS064131
  • Agency: CSRD VA, United States
    Id: I01 CX001006
  • Agency: BLRD VA, United States
    Id: IK2 BX002243
  • Agency: BLRD VA, United States
    Id: I01 BX002619
  • Agency: NIA NIH HHS, United States
    Id: T32 AG000057
  • Agency: NIA NIH HHS, United States
    Id: AG 000057-31

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


NSC-34 (tool)

RRID:CVCL_D356

Cell line NSC-34 is a Hybrid cell line with a species of origin Mus musculus (Mouse)

View all literature mentions

SH-SY5Y (tool)

RRID:CVCL_0019

Cell line SH-SY5Y is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HEK293 (tool)

RRID:CVCL_0045

Cell line HEK293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions